通阳祛瘀中药辅助化疗方案治疗Her—2阳性乳腺癌的临床效果(1)
[摘要] 目的 探討通阳祛瘀中药联合化疗方案治疗人类表皮生长因子受体2(Her-2)阳性乳腺癌患者的临床效果。 方法 选取2013年5月～2016年5月新疆维吾尔自治区中医医院收治的150例Her-2阳性乳腺癌患者，按随机数字表法分为对照组(75例)和观察组(75例)。分别给予曲妥珠单抗为主的化疗方案和通阳祛瘀中药联合化疗方案治疗，两组患者治疗时间均为18周。比较两组患者治疗前后中医证候积分、乳腺癌患者生命质量测定量表(FACT-B)评分、血液流变学指标水平、血清心肌肌钙蛋白(cTnI)、心型脂肪酸结合蛋白(H-FABP)、白介素-6(IL-6)、肿瘤坏死因子-a(TNF-α)及毒副作用差异。 结果 观察组患者客观缓解率和临床受益率均显著高于对照组(P < 0.05)。观察组患者治疗后中医证候积分显著低于对照组(P < 0.05)。观察组患者治疗后生理状况、社会家庭情况、情感情况、功能状况、附加关注等FACT-B指标评分低于对照组(P < 0.05)。观察组治疗后全血高切黏度、全血中切黏度、全血低切黏度、血浆黏度、cTnI、H-FABP、IL-6及TNF-α水平均显著低于对照组(P < 0.05)。观察组患者胃肠道反应、骨髓抑制、神经毒性、肝功能损伤、心脏毒性等毒副作用发生率较对照组显著降低(P < 0.05)。 结论 通阳祛瘀中药联合化疗方案治疗Her-2阳性乳腺癌可有效控制疾病进展，有较好的临床治疗效果，提高患者生活质量。
[关键词] 中医药；化疗；Her-2阳性；乳腺癌
[中图分类号] R73 [文献标识码] A [文章编号] 1673-7210(2017)09(a)-0089-05
[Abstract] Objective To investigate the clinical efficacy of Tongyang Quyu Decoction with combination chemotherapy scheme in the treatment of human epidermal growth factor receptor 2 (Her-2) positive breast cancer. Methods 150 cases with Her-2 positive breast cancer received in Traditional Chinese Medicine Hospital from May 2013 to May 2016 were divided into control group (75 cases) and observation group (75 cases) by random number table. The control group was treated with trastuzumab based chemotherapy， while the observation group was treated with Tongyang Quyu Decoction assisted with combination chemotherapy scheme. The two groups were treated for 18 weeks. The TCM Syndrome scores of breast cancer patients， quality of life scale (FACT-B) score， blood rheology， serum level of cardiac troponin (cTnI)， heart fatty acid binding protein (H-FABP)， interleukin -6 (IL-6) and tumor necrosis factor -a (TNF- alpha) and poison side effect difference in patients were compareds. Results The objective response rate and clinical benefit rate in the observation group were significantly higher than those in the control group (P < 0.05). The TCM Syndrome scores in the observation group after treatment were significantly lower than those in the control group (P < 0.05). The physiological status， family status， emotional status， social function， additional attention index FACT-B score in the observation group were lower than those in the control group (P < 0.05). Whole blood viscosity， whole blood viscosity， whole blood low shear viscosity， plasma viscosity， cTnI， H-FABP， IL-6 and TNF- levels of the observation group after treatment were significantly lower than those of the control group (P < 0.05). The incidence rate of observation group was lower than that of the control group (P < 0.05). Conclusion The treatment of Her-2 positive breast cancer with Tongyang Quyu Decoction with combination chemotherapy scheme can effectively control the progress of disease， have better clinical treatment effect and improve the quality of life of patients., 百拇医药(何娜娜 王巧琳 陈音)
[关键词] 中医药；化疗；Her-2阳性；乳腺癌
[中图分类号] R73 [文献标识码] A [文章编号] 1673-7210(2017)09(a)-0089-05
[Abstract] Objective To investigate the clinical efficacy of Tongyang Quyu Decoction with combination chemotherapy scheme in the treatment of human epidermal growth factor receptor 2 (Her-2) positive breast cancer. Methods 150 cases with Her-2 positive breast cancer received in Traditional Chinese Medicine Hospital from May 2013 to May 2016 were divided into control group (75 cases) and observation group (75 cases) by random number table. The control group was treated with trastuzumab based chemotherapy， while the observation group was treated with Tongyang Quyu Decoction assisted with combination chemotherapy scheme. The two groups were treated for 18 weeks. The TCM Syndrome scores of breast cancer patients， quality of life scale (FACT-B) score， blood rheology， serum level of cardiac troponin (cTnI)， heart fatty acid binding protein (H-FABP)， interleukin -6 (IL-6) and tumor necrosis factor -a (TNF- alpha) and poison side effect difference in patients were compareds. Results The objective response rate and clinical benefit rate in the observation group were significantly higher than those in the control group (P < 0.05). The TCM Syndrome scores in the observation group after treatment were significantly lower than those in the control group (P < 0.05). The physiological status， family status， emotional status， social function， additional attention index FACT-B score in the observation group were lower than those in the control group (P < 0.05). Whole blood viscosity， whole blood viscosity， whole blood low shear viscosity， plasma viscosity， cTnI， H-FABP， IL-6 and TNF- levels of the observation group after treatment were significantly lower than those of the control group (P < 0.05). The incidence rate of observation group was lower than that of the control group (P < 0.05). Conclusion The treatment of Her-2 positive breast cancer with Tongyang Quyu Decoction with combination chemotherapy scheme can effectively control the progress of disease， have better clinical treatment effect and improve the quality of life of patients., 百拇医药(何娜娜 王巧琳 陈音)